Close Menu

23andMe

Researchers uncovered nearly a hundred loci to general risk tolerance and hundreds more to particular risky behaviors.

With ever more data in hand, providers are seeking to enhance their services, providing more detailed ancestry estimates while introducing new offerings around genetic traits and health.

In Nature this week: Yemen cholera epidemic bacteria sequenced, loci linked to osteoporosis, and more.

As consumer genomics firms ramp up marketing for Alzheimer's risk tests, one  support group says experts should help people understand the results and potential negative effects.

Genome-wide association and meta-analyses have uncovered a dozen ADHD-related loci, providing insights into its biology and overlap with other conditions.

Myriad CEO Mark Capone said earnings during the quarter exceeded expectations based on strong volume growth from hereditary cancer and new products.

The genetic testing community is having a tough time deciphering FDA's intentions based on its authorization of 23andMe’s PGx test and a recent safety alert.

Few Eyebrows Up

Time reports that some experts have raised concerns about 23andMe's new direct-to-consumer pharmacogenetic tests.

The market authorization came with a number of caveats and special requirements that 23andMe must follow when selling its PGx tests to consumers.

Not the Whole Story

A genetic counselor-to-be warns in an op-ed in the Los Angeles Times that direct-to-consumer genetic tests only give a snapshot of genetic risk.

Pages

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.